A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This will be a single-blind, placebo-run-in trial. Subjects will be informed that they may
receive Venlafaxine or placebo during the course of the trial. All subjects will, in fact,
receive placebo for the first two weeks. All subjects will then be placed on 150-225 mg per
day of venlafaxine. Primary outcome assessment will compare pain intensity at 2 weeks (after
placebo) to that at 12 weeks (after 10 weeks of Venlafaxine treatment).
Study Hypothesis:
In subjects who continue to have activity-limiting osteoarthritis pain after treatment with
acetaminophen or non-steroidal anti-inflammatory agents, 150-225 mg Venlafaxine per day over
10 weeks will provide significant additional pain relief over that achieved with placebo
(more than 30% reduction after Venlafaxine treatment).